Search

Boehringer Ingelheim and Click Therapeutics Expand their Existing Collaboration to Develop Prescription Digital Therapeutics for Schizophrenia

Building Successful Partnerships in Animal Health

Christoph Vetten, Head of Transactions Animal Health, shares his perspectives on how building successful collaborations can drive innovation.

Boehringer included on LinkedIn’s “Top Companies 2024” list

Investing in our people is at the core of what we do

Outside the lab…inside the family

We are a manufacturing and a research company too. Outside of the lab, we have engineers, legal teams, logistics managers, QA/QC teams and more.

Efficacy and safety maintained in patients who switched from Humira® to biosimilar Cyltezo®

Partnering Interests

Biosimilars

Boehringer Ingelheim Pharmaceuticals, Inc. receives FDA approval for CyltezoTM (adalimumab-adbm)

Chronic Kidney Disease

Cyltezo® (adalimumab-adbm): First Interchangeable Biosimilar | BI US

Read more about how the FDA have approved CYLTEZO as the first interchangeable biosimilar with Humira®, supported by data from BI’s Phase III clinical trial.

US FDA approves the Cyltezo® Pen, a new autoinjector option, ahead of July 1 commercial launch

Cyltezo®, First Interchangeable Biosimilar to Humira®, Receives Preferred Formulary Status with Optum Rx for Commercially Insured Patients

Interchangeable Biosimilar Now on Express Scripts® Formulary

Boehringer Ingelheim’s Interchangeable biosimilar now included on Express Scripts National Preferred Formulary

Heart Diseases

Low-WAC interchangeable biosimilar is now available

Adalimumab-adbm, our interchangeable biosimilar to Humira, now available at a low wholesale acquisition cost.

Cyltezo®, first and only FDA-approved Interchangeable biosimilar to Humira®, now commercially available in the U.S.

FDA approves additional formulation of biosimilar

US FDA approves additional formulation of Cyltezo® (adalimumab-adbm). See Important Safety Information including Boxed Warning, Prescribing Information, Medication Guide and Instructions for Use.

New agreement with Quallent expands biosimilar access

Boehringer Ingelheim enters private label agreement for biosimilar

Diabetes

Biosimilar Cyltezo® demonstrates clinical equivalence to Humira® in patients with moderate-to-severe plaque psoriasis

Heart Failure

NVSS: The Future Vets & Scientists | Boehringer Ingelheim US

Click here to read more on the annual National Veterinary Scholars Symposium, celebrating future veterinarians and scientists across the USA.

Cardio-Renal-Metabolic diseases

Boehringer Ingelheim and Vanderbilt University join forces to develop new Ras inhibitors for cancer treatment

Boehringer Ingelheim and Vanderbilt University join forces

Boehringer Ingelheim and Gubra announce new collaboration to develop anti-obesity peptide poly-agonists

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers